

## **Gait variability and its progression over time in Parkinson's disease is linked to the cortical cholinergic system**

Kevin B. Wilkins<sup>1</sup>, Jordan E. Parker<sup>1</sup>, Helen M. Bronte-Stewart<sup>1,2</sup>

<sup>1</sup>Stanford University School of Medicine, Department of Neurology and Neurological Sciences, Stanford, CA, USA

<sup>2</sup>Stanford University School of Medicine, Department of Neurosurgery, Stanford, CA, USA

Corresponding Author:

Helen Bronte-Stewart MD MSE

John E. Cahill Family Professor,

Director, Stanford Movement Disorders Center (SMDC)

Department of Neurology and Neurological Sciences,

300 Pasteur Drive

Stanford University School of Medicine

Stanford CA 94305

Email: [hbs@stanford.edu](mailto:hbs@stanford.edu)

Keywords: gait, Nucleus Basalis of Meynert, Parkinson's disease, cholinergic, deep brain stimulation

Financial Disclosure/Conflict of Interest: Dr. Bronte-Stewart serves on a clinical advisory board for Medtronic, Inc.

Funding: This work was supported in part by the following: NINDS UH3NS107709, NINDS R21 NS096398-02, Michael J. Fox Foundation (9605), Robert and Ruth Halperin Foundation, John A. Blume Foundation, Smart Family Foundation, John E Cahill Family Foundation, and Medtronic Inc. who provided the devices used in this study but no additional financial support.

## Abstract

**Background:** Gait impairment has a detrimental effect on the lives of individuals with Parkinson's disease (PD). Although PD is typically characterized as a dopaminergic-depletion disorder, accumulating evidence implicates cholinergic dysfunction as an additional contributor. Whereas the dopaminergic system has been widely connected to cardinal motor signs, the cortical cholinergic system plays a crucial role in top-down cognitive processes that may be related to higher-order aspects of gait.

**Objective:** Investigate the relationship between higher-order gait control and the cortical cholinergic system separate from any disease-related dopaminergic deficits.

**Methods:** Twenty-two individuals with PD underwent structural MRI scans to assess gray matter volume of the Nucleus Basalis of Meynert (NBM), the key node in the cortical cholinergic network. Additionally, individuals performed a validated stepping-in-place task to assess gait variability and clinical motor assessments under several conditions: off all therapy, ON subthalamic nucleus (STN) deep brain stimulation (DBS), and off all therapy after three years of continuous DBS.

**Results:** Atrophy of the NBM was associated with greater (i.e., worse) gait variability off all therapy. STN DBS significantly improved cardinal motor signs but did not improve gait variability. Gait variability continued to decline over three years of continuous STN DBS, and NBM atrophy predicted the degree of decline. In contrast, three years of continuous STN DBS arrested progression of cardinal motor signs.

Conclusions: These results support a framework in which higher-order aspects of gait control are reliant on the cortical cholinergic system, separate from disease-related dopaminergic deficits, and which are not addressed by STN DBS.

## Introduction

Gait impairment and freezing of gait affect nearly 75% of individuals with advanced Parkinson's disease (PD)<sup>1</sup>. While bradykinesia, rigidity, tremor, and some aspects of gait impairment can be attributed to a dysfunctional dopaminergic system involving the basal ganglia, neuronal degeneration in PD is not limited to the basal ganglia nor the associated dopaminergic network. Neuronal degeneration and Lewy body formation also manifest in the basal forebrain, specifically in the Nucleus Basalis of Meynert (NBM), where degeneration begins early on in the disease progression of PD<sup>2,3</sup>. Although the NBM receives dopaminergic input, 80-90% of its cell makeup is cholinergic and it serves as the primary source of cholinergic innervation to the cortex<sup>4,5</sup>. Atrophy of this nucleus leads to major reductions in cortical acetylcholine (ACh) levels<sup>6,7</sup>, disrupting a wide range of high-level cognitive and executive functions. While the role of dopaminergic dysfunction has been well studied in PD, understanding how the NBM and cholinergic system relate to behavioral impairment in PD would allow better characterization of specific disease-related deficits and better inform future treatments.

In PD, atrophy of the NBM has been associated with cognitive deficits, as well as the worsening of cognition over time<sup>8-12</sup>. The NBM and cholinergic system appear to play an especially significant role in the cognitive domains of attention and visuospatial processing<sup>13-16</sup>. Recent evidence points to the influence of these cognitive domains on higher-order control of gait in PD<sup>17,18</sup>, with both freezing of gait and gait variability linked to deficits in attention switching,

visuospatial processing, and aspects of executive function<sup>19,20</sup>. However, the role of the NBM-cortical cholinergic system in higher-order aspects of gait is still unknown.

We propose that there may be an interplay between cognition, gait, and the cholinergic system, in which the cholinergic system serves as the common mechanism influencing function in both domains. Specifically, higher-order complex aspects of gait, such as gait variability, may be impacted by deficits in cortical cholinergic function. This would explain the oft observed progressive decline in aspects of gait in PD despite otherwise successful targeted dopaminergic therapies<sup>21,22</sup>. Current therapies, such as dopaminergic medical therapy or subthalamic nucleus (STN) deep brain stimulation (DBS), do not address deficits related to the cholinergic system. Instead, benefits from these therapies have been shown to improve lower-order aspects of gait that are more closely tied to dopamine and basal ganglia circuitry, such as step amplitude and gait speed<sup>22-24</sup>.

The goal of this study was to determine the relationship between the integrity of the NBM-cortical cholinergic system and the presence and longitudinal progression of gait variability in PD. We specifically quantified swing time variability since it has been shown to be a speed-independent measure of gait variability<sup>25</sup>. We also sought to determine the therapeutic effect of STN DBS on cardinal motor signs and gait variability, and whether after three years of STN DBS, there was evidence of progression of gait variability and/or cardinal motor signs, off all therapy. We hypothesized that atrophy of the NBM would be associated with greater impairment of higher-order aspects of gait, specifically gait variability. Additionally, we hypothesized that STN DBS would improve cardinal motor signs reliant on the dopaminergic system, but would not improve gait variability due to its reliance in part on the cortical cholinergic system. If these hypotheses were supported, we anticipated that gait variability would continue to decline despite successful,

continuous STN DBS, and that the degree of decline would be related to the amount of atrophy of the NBM. Meanwhile, cardinal motor signs would be slower in their decline due to the efficacy of STN DBS in targeting the dopaminergic system.

## **Materials and Methods**

### **Human Subjects**

Twenty-three individuals (16 males; age:  $59.2 \pm 10.1$ ; Table 1) with clinically established Parkinson's disease underwent bilateral implantation of DBS leads (model 3389, Medtronic., Inc) in the sensorimotor region of the STN. Post-operative CT scans were acquired as part of the standard clinical protocol<sup>26</sup>. The preoperative selection criteria, including neuropsychological testing and surgical technique, have been previously described<sup>26,27</sup>. All experimental testing was done in the off-medication state: long- and short-acting medications were withdrawn over 24 to 48 and 12 hours, respectively, and DBS therapy was turned off for at least 15 minutes before testing began for all non-DBS conditions<sup>28</sup>. All participants gave written informed consent to participate in the study, which was approved by the Stanford University Institutional Review Board.

### **Experimental Protocols**

#### **Clinical assessment of motor and gait impairment**

Clinical motor impairment was assessed using part III of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS III)<sup>29</sup>. The total score was also broken down into four bilateral sub-scores: axial, tremor, rigidity, and bradykinesia. Quantitative measures of gait were captured using the stepping-in-place (SIP) task, which is a validated metric of gait impairment and freezing<sup>30</sup> (Figure 1A). In the SIP task, participants completed 90 seconds of alternating, self-paced stepping on dual force plates.

All participants completed the SIP task and were evaluated using the UPDRS III at the Initial Programming (IP) visit, prior to activation of the DBS system. A subset of nineteen individuals completed the UPDRS III and the SIP task ON and OFF STN DBS at a time point between IP and the three-year visit. Lastly, a subset of eleven individuals completed the UPDRS III and SIP task after three years of continuous DBS, off all therapy.

### **Kinetic data acquisition and analysis**

During the SIP task, ground reaction forces were captured at either 100 or 1000 Hz, using the Smart Equitest or Bertec systems, respectively (Neurocom Inc., Clackamas, OR, USA; Bertec Corporation, Columbus, OH, USA). Swing time was defined as the duration between when one foot left the force plate and when the same foot contacted the force plate again, Figure 1B. Gait variability was defined as the mean swing time coefficient of variation (CV = standard deviation/mean). A larger swing time CV is indicative of more variable gait and has been shown to be independent of gait speed and shows high reliability<sup>25,31</sup>. Data were log transformed to conform to normality. A previously validated computerized algorithm was used to identify freezing episodes<sup>30</sup>.

### **MRI Acquisition and Analysis**

Pre-operative MRI scans were acquired as part of the standard clinical protocol previously described<sup>26</sup>. T1-structural scans were performed at Stanford Hospital and Clinics on a 3T Discovery MR750 scanner with a 32-channel head coil. The scans had an isotropic voxel resolution of  $1 \times 1 \times 1 \text{ mm}^3$  (TR=8.24ms, TE=3.24ms, FOV= 240x240mm<sup>2</sup>).

### **MRI Preprocessing**

Voxel-based morphometry was applied to T1 images using SPM12 software (Statistical Parametric Mapping 12; Wellcome Trust Centre for Neuroimaging, UCL, London, UK). Images were automatically segmented into gray matter, white matter, and cerebrospinal fluid with 1.5 mm<sup>3</sup> resolution. The extracted gray and white matter were nonlinearly registered to Montreal Neurological Institute (MNI) space using the Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra algorithm (DARTEL). The gray matter was then warped using the individual flow fields resulting from the DARTEL registration, and voxel values were modulated for volumetric changes introduced by the high dimensional normalization to ensure that the total amount of gray matter volume was preserved. Images were then smoothed to account for anatomical variability across individuals to facilitate statistical comparison. The NBM was identified and masked using probabilistic anatomical maps available in the Anatomy Toolbox. These maps were created from histological post-mortem analysis of 10 brains<sup>32</sup>.

### **Localization of DBS Leads**

Locations of DBS leads were determined by the Lead-DBS toolbox<sup>33</sup> based on preoperative T1 and T2 MRIs and postoperative CT scans. Postoperative CT scans and preoperative T2 scans were co-registered to preoperative T1 scans, which were then normalized into MNI space using SPM12 and Advanced Normalization Tools<sup>34</sup>. DBS electrode localizations were corrected for brain-shift in the postoperative CT scan<sup>35</sup>. DBS electrodes were then localized in template space using the PaCER algorithm<sup>36</sup> and projected onto the DISTAL Atlas to visualize overlap with the STN<sup>37</sup>.

### **Statistical Analysis**

Voxel-wise statistics for associations between swing time variability in the SIP task and gray matter volume within the NBM were computed using a general linear model in SPM12. These

associations were also computed for percent change in swing time variability from IP to 3 years later and gray matter volume within the NBM. We used total intracranial volume (i.e., total white matter, gray matter, and CSF) for each individual as a global normalization to deal with brains of different sizes. A multiple regression model was used to assess any association between gray volume and SIP behavior, considering age and sex as covariates. Significance was set at  $p < 0.005$  uncorrected with a cluster threshold of 10 voxels. Paired t-tests were used to compare the effect of DBS (ON vs. OFF) on gait variability on the SIP task and change in UPDRS scores. Additionally, paired t-tests were used to compare changes in gait variability and UPDRS from IP to 3 years later. Significance was set at  $p < 0.05$ .

## Results

### **NBM Atrophy was associated with greater swing time variability**

Of the full cohort of twenty-three individuals, one was excluded due to movement artifacts in their T1 scan. For the remaining twenty-two individuals, we compared swing time variability in the SIP task at the Initial Programming (IP) visit, Figure 1A and B, with NBM gray matter volume, Fig. 1C, using a multiple regression model. The IP visit occurred  $63.9 \pm 31.9$  days after the MRI scan. Multiple clusters were found bilaterally within the NBM where lower gray matter volume was significantly associated with greater (i.e., worse) swing time variability, Fig. 1D ( $p < 0.005$ ). Information on each cluster is shown in Supplementary Table 1.






Figure 1. NBM atrophy was associated with greater swing time variability. (A) Depiction of the stepping-in-place (SIP) task in which the patient alternately steps on two force plates. (B) A representative trace from the SIP task showing the stepping cycles. The red line represents the stepping trace of the right foot and the blue line represents that of the left foot. The highlighted portion represents the period of time when the left foot was in the swing phase: from when the foot left the force plate to the point when it returned (arrows). The swing time coefficient of variation (standard deviation/mean) was calculated as a measure of gait variability. (C) Probabilistic mask of the Nucleus Basalis of Meynert (NBM) in MNI space as determined previously by Zaborszky et al., 2008. The color bar represents the probability that the voxel was identified as NBM in that cohort. (D) Voxels showing a significant negative correlation between NBM gray matter volume and swing time variability on the SIP task at Initial Programming (IP). Individuals with lower gray matter volume in the NBM show greater (i.e., worse) swing time variability. The color bar represents t-values. MNI coordinates of each slice are shown at the bottom.

### DBS improved cardinal motor signs but not swing time variability

Nineteen individuals were assessed with the UPDRS III and completed the SIP task OFF and ON STN DBS within the same visit at a timepoint between IP and 3 years. Figure 2A demonstrates that the STN DBS leads were located within the STN for all individuals. All testing was performed off medication.

We compared whether cardinal motor signs of tremor, rigidity, bradykinesia, and axial motor function changed in response to DBS using the UPDRS III. Cardinal motor signs all improved ON compared to OFF STN DBS, as shown by the reduced total UPDRS III scores, Fig. 2B ( $t(18) = 9.14$ ,  $p = 3.5e-8$ ) and all of its sub-scores, Fig. 2C, which included axial ( $t(18) = 5.81$ ,  $p = 1.65e-5$ ), tremor ( $t(18) = 5.21$ ,  $p = 5.93e-5$ ), rigidity ( $t(18) = 5.90$ ,  $p = 1.37e-5$ ), and bradykinesia ( $t(18) = 6.12$ ,  $p = 8.80e-6$ ).

Unlike the cardinal motor signs, STN DBS did not improve swing time variability compared to OFF DBS, Fig. 2D ( $t(18) = 0.89$ ,  $p = 0.39$ ).




Figure 2. STN DBS improved cardinal motor signs but did not improve swing time variability. (A) DBS electrode lead placement in the STN (orange) for 19 participants. (B) Comparison of total UPDRS III and (C) its sub-scores OFF (blue) and ON (pink) DBS. STN DBS reduced total UPDRS-III and all of its sub-scores. (D) Comparison of swing time variability during the SIP task OFF and ON DBS. STN DBS did not improve swing time variability. Error bars represent SEM. \* indicates significant differences.

### **NBM atrophy predicted the decline in swing variability**

After three years of continuous STN DBS, a subset of eleven individuals were assessed off all therapy (i.e., off DBS and dopaminergic medication) for changes in the UPDRS III and in swing time variability during the SIP task. A SIP trace from a representative individual at IP and at the three-year timepoint is depicted in Figure 3A and B.

This individual performed 90 seconds of regular alternating stepping without freezing at IP, Fig. 3A; three years later, the patient demonstrated more arrhythmic stepping and experienced two freezing episodes (vertical green lines) during which they were unable to lift either foot off the force plates, Fig. 3B. This individual observation of gait deterioration was supported by the fact that swing time variability for the group increased (worsened), over time, Fig. 3C ( $t(10) = 4.42$ ;  $p = 0.001$ ).

A multiple regression model found a significant cluster within the NBM where lower gray matter volume was significantly associated with greater increase of swing time variability, Fig. 3D ( $p < 0.005$ ). Information on this cluster is shown in Supplementary Table 2.




Figure 3. Swing time variability increased over time, off therapy, and the degree of increase was related to initial levels of NBM atrophy. (A) Example of a kinetic trace during the stepping-in-place (SIP) task at Initial Programming (IP) and (B) three years later in the same individual where freezing episodes are denoted by green vertical lines. (C) Comparison of swing time variability during the SIP task at IP (blue) and 3 years (pink). Swing time variability significantly increased (i.e., worsened) over time. (D) Voxels showing a significant negative correlation between gray matter volume and percent change in swing time variability on the SIP task from IP to 3 years later. Individuals with lower gray matter volume showed greater increases in swing time variability over time. The color bar represents t-values. MNI coordinates of each slice are shown at the bottom. Error bars represent SEM. \* indicates significant differences.<sup>13</sup>

## Continuous DBS stalled progression of cardinal motor signs measured off therapy

In contrast to the worsening of swing time variability, there was no change in UPDRS III, off therapy, between IP and the three-year timepoint, Figure 4A ( $t(10) = 0.36$ ,  $p = 0.73$ ). This held true for all sub-scores, Fig. 4B, including axial ( $t(10) = 0.54$ ,  $p = 0.60$ ), tremor ( $t(10) = 1.31$ ,  $p = 0.22$ ), rigidity ( $t(10) = 1.27$ ,  $p = 0.23$ ), and bradykinesia ( $t(10) = 0.89$ ,  $p = 0.40$ ) indicating that there was no observable decline in cardinal motor signs over time, off therapy, after three years of continuous STN DBS.




Figure 4. Cardinal motor signs did not worsen over time, measured off therapy, after three years of continuous STN DBS. (A) Total UPDRS III and (B) its sub-scores at IP (blue) and 3 years later (pink) tested off of all therapy. Error bars represent SEM.

## Discussion

The current study investigated the relationship between gray matter structure of the Nucleus Basalis of Meynert (NBM), the central node in the cortical cholinergic system, and gait impairment in individuals with PD through a combination of structural imaging, quantitative gait analysis, and STN DBS. We demonstrated, for the first time, that atrophy of the NBM, which results in degeneration of the forebrain-cortical cholinergic system, was associated with greater gait variability in individuals with PD. STN DBS, which targets the degenerating dopaminergic system in PD, did not improve deficits in gait variability despite overall improvements in tremor, rigidity, bradykinesia, and axial motor function. It was evident that, off therapy, gait variability continued to worsen over three years, and the amount of atrophy of NBM predicted the degree of worsening of gait variability. In contrast, there was no progression in cardinal motor signs, off therapy, after three years of continuous STN DBS. Together, these results point towards a critical role of the cortical cholinergic system in gait variability in PD, separate from dopaminergic-related deficits in cardinal motor signs, and give insight into the limitations of STN DBS in ameliorating specific domains of gait impairment.

### **The influence of the cholinergic system on gait variability**

Gait variability is a metric that requires higher-order control in PD compared to healthy controls: although both healthy controls and individuals with PD will decrease speed in response to a demanding dual task, only PD show increases in gait variability, such as swing time variability<sup>38</sup>. This suggests that individuals with PD show deficits in the automaticity of gait, and increasingly rely on cognitive-related functions to compensate. Additionally, greater gait variability during walking is associated with greater sensorimotor activity, suggesting a role of top-down processing<sup>39,40</sup>. The stepping-in-place task used here, may be especially effective at highlighting the higher-order contributions to gait variability considering optic flow is minimized, so sensory-

related guidance of stepping is more limited compared to forward walking. It has been shown that increased gait variability was associated with impairment in certain cognitive domains in PD, some of which may be related to the cholinergic system<sup>18–20,41</sup>. However, there has been no link between gait variability and the cholinergic system until now, despite theoretical predictions<sup>42</sup>. The results of this study demonstrate for the first time that atrophy of the NBM, the key node in the cortical cholinergic network, was related to greater (i.e., worse) gait variability in PD, thus providing evidence that the cholinergic system plays a significant role in the underlying mechanism contributing to impairment of higher-order aspects of gait.

The observed relationship between the cholinergic system and gait variability continues to build on the evidence that PD is not merely a hypodopaminergic disease, but rather a multisystem neurodegenerative disorder<sup>43</sup>. This points to the reliance of higher-order aspects of gait (stepping control) on the cholinergic system, possibly through its effects on attention and other cognitive processes that may become increasingly critical as the automaticity of gait becomes more impaired. Previously, it has been shown that levels of cortical ACh were related to gait speed during forward walking in PD<sup>43,44</sup>. However, gait speed is also intertwined with the dopaminergic network as both levodopa and STN DBS consistently improve gait speed<sup>24,45,46</sup>. We show that swing time variability, a metric independent of gait speed, is related to the integrity of a key node in the cortical cholinergic network. We propose therefore that a compromised cholinergic system negatively impacts higher-order aspects of gait control. This idea is supported by pharmacological evidence showing that increasing ACh levels via administration of acetylcholinesterase inhibitors improved both attention<sup>47</sup> and step variability in PD<sup>48</sup>. Within this framework, the cholinergic system appears to be the common denominator in the interplay between gait and cognition, leaving both processes susceptible to decline in PD as the NBM deteriorates.



Although the NBM is the key node in the cortical cholinergic system, the pedunculopontine nucleus (PPN) provides cholinergic input at the level of the brainstem and to the thalamus and is implicated in gait impairment in PD<sup>49-51</sup>. The PPN is strongly related to falls and posture<sup>52,53</sup>, and its position in the brainstem allows it to serve as a final outflow block influencing gait<sup>54</sup>. Whereas the PPN modulates bottom-up processing<sup>55</sup>, the cortical cholinergic system strongly correlates with cognitive deficits<sup>56,57</sup> and other higher-order top-down processes<sup>58</sup>. It is also possible that the two systems interact at the level of the thalamus or brainstem to impact aspects of gait<sup>59,60</sup>.

### **Differentiating the mechanisms of cardinal motor signs and gait variability with STN DBS**

As expected, STN DBS improved cardinal motor signs of PD as assessed by the UPDRS III; however, STN DBS did not improve gait variability, which supports previous evidence on the inconsistency of the efficacy of dopaminergic therapies on gait variability and swing time asymmetry<sup>22,61-64</sup>. The observed differences in efficacy of STN DBS on gait variability compared to its effect on cardinal motor signs suggest that different mechanisms may underlie these processes. Although STN DBS targets the cortico-basal ganglia circuitry and the associated dopaminergic network to improve motor function, gait is a highly complex process that also encompasses non-motor related mechanisms such as executive function, attention, and visuospatial processing<sup>17</sup>. STN DBS may successfully address cardinal motor signs by targeting the malfunctioning basal ganglia dopaminergic network; however, if certain aspects of gait, such as gait variability, also rely on compromised circuitries unrelated to the cortico-basal ganglia network, one would not expect these aspects of gait to effectively respond to DBS. The lack of improvement in gait variability observed here builds on the evidence that it is strongly influenced by higher-level mechanisms that rely more heavily on other networks, such as the cholinergic system.

## **Long-term progression of gait variability and cardinal motor signs**

Off therapy gait variability continued to worsen over three years whereas cardinal motor signs did not decline following continuous STN DBS. This result expands on the earlier finding that DBS did not improve gait variability and suggests that the observed worsening of gait variability is a manifestation of progressing neuropathology in non-dopaminergic networks. Continuous STN DBS appeared to alter the expected decline of cardinal motor signs, measured off all therapy, over three years. This finding builds on previous work from our lab that continuous neuromodulation of the sensorimotor network via STN DBS may alter the progression of cardinal motor signs<sup>28</sup>. However, this effect is limited to symptoms reliant on the cortico-basal ganglia and associated dopaminergic system. Any disease-modifying effect of STN DBS on the dopaminergic system would not address, nor stall, NBM degeneration or the gait dysfunction that is associated with lack of cholinergic integrity. Instead, higher-order aspects of gait reliant on cholinergic function continued to decline with disease progression.

## **NBM atrophy predicts worsening of gait variability over time**

The degree of atrophy of the NBM predicted the observed increase (worsening) of gait variability three years after initial evaluation. It has been shown that atrophy of the NBM and its microstructure predicted cognitive decline several years later in PD<sup>8,10,11</sup>. Considering that NBM degeneration occurs early on in the disease process in PD<sup>65,66</sup>, there is a growing need to find ways of intervening before any accumulating effects start significantly impacting behavior, especially cognition. The link between NBM, cognition, and gait may point towards a potential role for swing time variability as a simple measure to serve as a “canary in the coal mine” to predict impairment in cortical cholinergic networks and subsequent decline in higher-order control of gait, and to serve as a measure of efficacy of novel therapeutic interventions. Such a measure could be crucial to

allow for identification of patients who may benefit from early interventions to prevent consequences of increasing gait variability, such as freezing of gait and falls<sup>42</sup>.

## **Limitations**

One possible limitation is that different Parkinsonian signs may return at different rates after discontinuing STN DBS. For instance, axial symptoms return more gradually than tremor<sup>67</sup>. During the DBS visit and at the three-year follow-up, DBS was turned off at least 15 minutes prior to testing; we have shown that beta band power, a neural biomarker of hypokinetic aspects of PD, returned to baseline within this timeframe after DBS was turned off<sup>28</sup>. Axial symptoms respond much faster when going from the OFF to ON state<sup>67</sup>, so it is unlikely that the ON DBS condition represented a sub-optimal stimulation state. Another limitation was no follow-up MRI to track the change in NBM atrophy alongside the decline in gait variability. Future studies should combine both quantitative metrics of gait with longitudinal MRIs to further investigate the predictive power of the NBM for gait impairment and vice versa.

## **Conclusions**

The current study demonstrated that deficits in swing time variability, a measure of gait variability that is independent of gait speed, in PD were related to a compromised cortical cholinergic system: greater swing time variability was associated with lower gray matter volume in the NBM, the key node in the cortical cholinergic network. Deficits in swing time variability were independent from the dopaminergic system since STN DBS, which improved cardinal motor signs of tremor, rigidity, bradykinesia, and axial motor function, did not improve gait variability. Furthermore, swing time variability continued to decline over three years of continuous STN DBS, and pre-operative NBM atrophy was a predictor of worsening swing time variability. In contrast, after three years of

continuous STN DBS, cardinal motor signs measured off therapy were no different from those prior to activation of the DBS system. The above results support a framework in which higher-order aspects of gait control may be reliant on cortical cholinergic processing. Swing time variability is a readily accessible measure of impairment that could provide insight into cortical cholinergic networks in PD and identify individuals who may benefit from early interventions to prevent the devastating behavioral manifestations of the degeneration of the cortical cholinergic system over the course of PD.

### **Acknowledgements**

We would like to thank the members of the Human Motor Control and Neuromodulation lab, Dr. Jaimie Henderson, and, most importantly, the participants who dedicated their time to this study.

**Table 1. Patient Demographics**

Patient	Age (Years)	Sex	Time Since Diagnosis (Years)	Pre-Op UPDRS III (off meds)	Pre-Op UPDRS III (on meds)	UPDRS III (ON STN DBS, off meds)
1	72.9	M	9.9	54	41	24
2	52.8	M	4.9	24	8	5
3	62.5	M	3.0	35	26	11
4	65.7	M	5.2	29	16	12
5	58.1	M	3.4	39	23	19
6	42.2	M	4.5	58	12	9
7	69.0	M	10.6	41	28	14
8	53.5	M	7.6	52	29	17
9	73.1	F	8.8	37	22	-
10	72.2	M	8.9	47	23	29
11	58.6	F	10.0	33	6	18
12	54.5	M	11.0	56	20	20
13	34.3	M	2.1	59	22	-
14	57.3	M	6.1	62	23	19
15	67.6	F	6.1	44	25	2
16	50.6	F	9.2	50	26	14
17	61.9	M	14.3	42	24	8
18	52.0	F	12.5	34	6	6
19	66.1	M	7.6	51	10	-
20	56.8	F	11.6	38	18	8
21	75.7	F	8.5	44	19	-
22	55.0	M	10.4	11	7	2
23	50.1	M	10.2	38	31	17
Average	59.2		8.1	42.5	20.2	21.3
$\pm$	$\pm$		$\pm$	$\pm$	$\pm$	$\pm$
SD	10.1		3.2	11.9	8.7	13.1

## References

1. Panisset, M. Freezing of gait in Parkinson's disease. *Neurol Clin* **22**, S53-62 (2004).
2. Nakano, I. & Hirano, A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. *Ann. Neurol.* **15**, 415–418 (1984).
3. Rogers, J. D., Brogan, D. & Mirra, S. S. The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. *Ann. Neurol.* **17**, 163–170 (1985).
4. Mesulam, M. M., Mufson, E. J., Levey, A. I. & Wainer, B. H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. *J. Comp. Neurol.* **214**, 170–197 (1983).
5. Mesulam, M.-M. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. *Journal of Comparative Neurology* **521**, 4124–4144 (2013).
6. Johnston, M. V., McKinney, M. & Coyle, J. T. Evidence for a cholinergic projection to neocortex from neurons in basal forebrain. *Proc. Natl. Acad. Sci. U.S.A.* **76**, 5392–5396 (1979).
7. Mufson, E. J., Martin, T. L., Mash, D. C., Wainer, B. H. & Mesulam, M. M. Cholinergic projections from the parabigeminal nucleus (Ch8) to the superior colliculus in the mouse: a combined analysis of horseradish peroxidase transport and choline acetyltransferase immunohistochemistry. *Brain Res.* **370**, 144–148 (1986).
8. Ray, N. J. *et al.* In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease. *Brain* **141**, 165–176 (2018).

9. Barrett, M. J. *et al.* Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease. *J. Neurol. Neurosurg. Psychiatry* **90**, 1251–1256 (2019).
10. Schulz, J., Pagano, G., Fernández Bonfante, J. A., Wilson, H. & Politis, M. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease. *Brain* **141**, 1501–1516 (2018).
11. Pereira, J. B. *et al.* Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease. *Neurobiology of Disease* **139**, 104831 (2020).
12. Gang, M. *et al.* Clinical and Cerebral Metabolic Changes in Parkinson’s Disease With Basal Forebrain Atrophy. *Movement Disorders* **n/a**,.
13. Klinkenberg, I., Sambeth, A. & Blokland, A. Acetylcholine and attention. *Behav. Brain Res.* **221**, 430–442 (2011).
14. Bohnen, N. I. *et al.* Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. *J. Neurol.* **253**, 242–247 (2006).
15. Gratton, C. *et al.* Cholinergic, But Not Dopaminergic or Noradrenergic, Enhancement Sharpens Visual Spatial Perception in Humans. *J Neurosci* **37**, 4405–4415 (2017).
16. Ballinger, E. C., Ananth, M., Talmage, D. A. & Role, L. W. Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. *Neuron* **91**, 1199–1218 (2016).
17. Amboni, M., Barone, P. & Hausdorff, J. M. Cognitive Contributions to Gait and Falls: Evidence and Implications. *Mov Disord* **28**, 1520–1533 (2013).
18. Yao, Z., Shao, Y. & Han, X. Freezing of gait is associated with cognitive impairment in patients with Parkinson disease. *Neurosci. Lett.* **656**, 126–130 (2017).

19. Amboni, M., Cozzolino, A., Longo, K., Picillo, M. & Barone, P. Freezing of gait and executive functions in patients with Parkinson's disease. *Mov. Disord.* **23**, 395–400 (2008).
20. Nantel, J., McDonald, J. C., Tan, S. & Bronte-Stewart, H. Deficits in visuospatial processing contribute to quantitative measures of freezing of gait in Parkinson's disease. *Neuroscience* **221**, 151–156 (2012).
21. Smulders, K., Dale, M. L., Carlson-Kuhta, P., Nutt, J. G. & Horak, F. B. Pharmacological treatment in Parkinson's disease: effects on gait. *Parkinsonism Relat Disord* **31**, 3–13 (2016).
22. Blin, O., Ferrandez, A. M., Pailhous, J. & Serratrice, G. Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease. *J. Neurol. Sci.* **103**, 51–54 (1991).
23. Yttri, E. A. & Dudman, J. T. A Proposed Circuit Computation in Basal Ganglia: History-Dependent Gain. *Mov Disord* **33**, 704–716 (2018).
24. Roper, J. A. *et al.* Deep brain stimulation improves gait velocity in Parkinson's disease: a systematic review and meta-analysis. *J. Neurol.* **263**, 1195–1203 (2016).
25. Frenkel-Toledo, S. *et al.* Effect of gait speed on gait rhythmicity in Parkinson's disease: variability of stride time and swing time respond differently. *J Neuroeng Rehabil* **2**, 23 (2005).
26. Brontë-Stewart, H., Louie, S., Batya, S. & Henderson, J. M. Clinical motor outcome of bilateral subthalamic nucleus deep-brain stimulation for Parkinson's disease using image-guided frameless stereotaxy. *Neurosurgery* **67**, 1088–1093; discussion 1093 (2010).
27. Quinn, E. J. *et al.* Beta oscillations in freely moving Parkinson's subjects are attenuated during deep brain stimulation. *Mov. Disord.* **30**, 1750–1758 (2015).



28. Trager, M. H. *et al.* Subthalamic beta oscillations are attenuated after withdrawal of chronic high frequency neurostimulation in Parkinson's disease. *Neurobiol. Dis.* **96**, 22–30 (2016).
29. Goetz, C. G. *et al.* Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. *Mov. Disord.* **22**, 41–47 (2007).
30. Nantel, J., de Solages, C. & Bronte-Stewart, H. Repetitive stepping in place identifies and measures freezing episodes in subjects with Parkinson's disease. *Gait Posture* **34**, 329–333 (2011).
31. Arcolin, I. *et al.* Proposal of a new conceptual gait model for patients with Parkinson's disease based on factor analysis. *BioMedical Engineering OnLine* **18**, 70 (2019).
32. Zaborszky, L. *et al.* Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. *Neuroimage* **42**, 1127–1141 (2008).
33. Horn, A. *et al.* Lead-DBS v2: Towards a comprehensive pipeline for deep brain stimulation imaging. *NeuroImage* **184**, 293–316 (2019).
34. Avants, B. B., Epstein, C. L., Grossman, M. & Gee, J. C. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. *Med Image Anal* **12**, 26–41 (2008).
35. Horn, A. & Kühn, A. A. Lead-DBS: a toolbox for deep brain stimulation electrode localizations and visualizations. *Neuroimage* **107**, 127–135 (2015).
36. Husch, A., V. Petersen, M., Gemmar, P., Goncalves, J. & Hertel, F. PaCER - A fully automated method for electrode trajectory and contact reconstruction in deep brain stimulation. *NeuroImage: Clinical* **17**, 80–89 (2018).

37. Ewert, S. *et al.* Toward defining deep brain stimulation targets in MNI space: A subcortical atlas based on multimodal MRI, histology and structural connectivity. *NeuroImage* **170**, 271–282 (2018).
38. Yogev, G. *et al.* Dual tasking, gait rhythmicity, and Parkinson’s disease: which aspects of gait are attention demanding? *Eur. J. Neurosci.* **22**, 1248–1256 (2005).
39. Kurz, M. J., Wilson, T. W. & Arpin, D. J. Stride-time variability and sensorimotor cortical activation during walking. *Neuroimage* **59**, 1602–1607 (2012).
40. Berger, A. *et al.* Increased gait variability during robot-assisted walking is accompanied by increased sensorimotor brain activity in healthy people. *J Neuroeng Rehabil* **16**, 161 (2019).
41. Morris, R. *et al.* Gait Rather Than Cognition Predicts Decline in Specific Cognitive Domains in Early Parkinson’s Disease. *J. Gerontol. A Biol. Sci. Med. Sci.* **72**, 1656–1662 (2017).
42. Morris, R. *et al.* Overview of the cholinergic contribution to gait, balance and falls in Parkinson’s disease. *Parkinsonism Relat. Disord.* **63**, 20–30 (2019).
43. Bohnen, N. I. *et al.* Gait speed in Parkinson disease correlates with cholinergic degeneration. *Neurology* **81**, 1611–1616 (2013).
44. Rochester, L. *et al.* Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s disease. *Brain* **135**, 2779–2788 (2012).
45. Ferrarin, M. *et al.* Effects of bilateral subthalamic stimulation on gait kinematics and kinetics in Parkinson’s disease. *Exp Brain Res* **160**, 517–527 (2005).
46. Stolze, H. *et al.* Effects of bilateral subthalamic nucleus stimulation on parkinsonian gait. *Neurology* **57**, 144–146 (2001).
47. Wesnes, K. A., McKeith, I., Edgar, C., Emre, M. & Lane, R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. *Neurology* **65**, 1654–1656 (2005).

48. Henderson, E. J. *et al.* Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet Neurology* **15**, 249–258 (2016).
49. Lau, B. *et al.* The integrative role of the pedunculopontine nucleus in human gait. *Brain* **138**, 1284–1296 (2015).
50. Jenkinson, N. *et al.* Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. *Movement Disorders* **24**, 319–328 (2009).
51. Thevathasan, W. *et al.* Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review. *Movement Disorders* **33**, 10–20 (2018).
52. Müller, M. L. T. M. *et al.* Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. *Brain* **136**, 3282–3289 (2013).
53. Kucinski, A., de Jong, I. E. M. & Sarter, M. Reducing falls in Parkinson's disease: interactions between donepezil and the 5-HT<sub>6</sub> receptor antagonist idalopirdine on falls in a rat model of impaired cognitive control of complex movements. *Eur. J. Neurosci.* **45**, 217–231 (2017).
54. Lewis, S. J. G. & Shine, J. M. The Next Step: A Common Neural Mechanism for Freezing of Gait. *Neuroscientist* **22**, 72–82 (2016).
55. Kim, K., Müller, M. L. T. M., Bohnen, N. I., Sarter, M. & Lustig, C. Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson's Disease patients with defined cholinergic losses. *Neuroimage* **149**, 295–304 (2017).
56. Bohnen, N. I. *et al.* Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. *J. Cereb. Blood Flow Metab.* **32**, 1609–1617 (2012).

57. Bohnen, N. I. *et al.* Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. *JAMA Neurol* **72**, 194–200 (2015).
58. Kim, K., Müller, M. L. T. M., Bohnen, N. I., Sarter, M. & Lustig, C. The cortical cholinergic system contributes to the top-down control of distraction: Evidence from patients with Parkinson’s disease. *NeuroImage* **190**, 107–117 (2019).
59. Hallanger, A. E., Levey, A. I., Lee, H. J., Rye, D. B. & Wainer, B. H. The origins of cholinergic and other subcortical afferents to the thalamus in the rat. *J. Comp. Neurol.* **262**, 105–124 (1987).
60. Parent, A., Paré, D., Smith, Y. & Steriade, M. Basal forebrain cholinergic and noncholinergic projections to the thalamus and brainstem in cats and monkeys. *J. Comp. Neurol.* **277**, 281–301 (1988).
61. Curtze, C., Nutt, J. G., Carlson-Kuhta, P., Mancini, M. & Horak, F. B. Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson’s Disease. *Mov. Disord.* **30**, 1361–1370 (2015).
62. Lord, S., Baker, K., Nieuwboer, A., Burn, D. & Rochester, L. Gait variability in Parkinson’s disease: an indicator of non-dopaminergic contributors to gait dysfunction? *J. Neurol.* **258**, 566–572 (2011).
63. Bryant, M. S. *et al.* Gait variability in Parkinson’s disease: influence of walking speed and dopaminergic treatment. *Neurol. Res.* **33**, 959–964 (2011).
64. Anidi, C. *et al.* Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson’s disease. *Neurobiol. Dis.* **120**, 107–117 (2018).

65. Braak, H. *et al.* Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol. Aging* **24**, 197–211 (2003).
66. Shimada, H. *et al.* Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. *Neurology* **73**, 273–278 (2009).
67. Temperli, P. *et al.* How do parkinsonian signs return after discontinuation of subthalamic DBS? *Neurology* **60**, 78–81 (2003).